A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.
Hyun-Sung LeeHee-Jin JangMaheshwari RamineniDaniel Y WangDaniela RamosJong Min ChoiTaylor SplawnMonica EspinozaMichelle AlmarezLeandria HoseyEunji JoSusan G HilsenbeckChristopher Ian AmosR Taylor RipleyBryan M BurtPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
These data indicate that neoadjuvant durvalumab plus tremelimumab orchestrates de novo systemic immune responses that extend to the tumor microenvironment and correlate with favorable clinical outcomes.